Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb;21(4):463-471.
doi: 10.1080/14796694.2024.2445499. Epub 2024 Dec 23.

A nomogram with coagulation markers for prostate cancer prediction in patients with PSA levels of 4-20 ng/mL

Feifan Liu  1   2 , Jianyu Wang  1 , Yufeng Song  3 , Fei Wu  1   2 , Haihu Wu  1   2 , Jiaju Lyu  1   2 , Hao Ning  1   2
Affiliations

A nomogram with coagulation markers for prostate cancer prediction in patients with PSA levels of 4-20 ng/mL

Feifan Liu et al. Future Oncol. 2025 Feb.

Abstract

Background: The global incidence of prostate cancer (PCa) is rising, necessitating improved diagnostic strategies. This study explores coagulation parameters' predictive value for clinically significant PCa (csPCa) and develops a nomogram.

Research design and methods: This study retrospectively analyzed data from 702 patients who underwent prostate biopsy at Shandong Provincial Hospital (SDPH) and 142 patients at Shandong Cancer Hospital and Institute (SDCHI). SDPH patients were randomly assigned at a 7:3 ratio for internal validation, while SDCHI data served as external validation. LASSO and logistic regression identified the best predictive factors for csPCa, which were used to construct a model. The model's efficacy was tested using AUC, calibration curves, and decision curve analysis.

Results: TPSA, age, D-dimer, prostate volume (PV), and digital rectal examination (DRE) were identified as independent risk factors for csPCa. A predictive model was constructed using a nomogram. The AUC for the training set was 0.841, for internal validation 0.809, and for external validation 0.814. Calibration and decision curves confirmed the model's clinical utility.

Conclusions: The nomogram incorporating D-dimer, TPSA, age, PV, and DRE provides a highly accurate tool for assessing csPCa risk in individuals with PSA levels of 4-20 ng/mL, supporting personalized diagnostics and clinical decision-making.

Keywords: D-dimer; Prostate cancer; diagnosis; nomogram; prostate biopsy.

PubMed Disclaimer

Conflict of interest statement

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

References

    1. Cao H, Wang Y, Zhang D, et al. Periprostatic adipose tissue: a new perspective for diagnosing and treating prostate cancer. J Cancer. 2024;15(1):204–217. - PMC - PubMed
    1. de Vos II, Remmers S, Hogenhout R, et al. Prostate cancer mortality among elderly men after discontinuing organised screening: long-term results from the European randomized study of screening for prostate cancer Rotterdam. Eur Urol. 2024;85(1):74–81. - PubMed
    1. Chen H, Qian Y, Wu Y, et al. Modified prostate health index density significantly improves clinically significant prostate cancer (csPca) detection. Front Oncol. 2022;12:864111. - PMC - PubMed
    1. Heijnsdijk EA, der Kinderen A, Wever EM, et al. Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer. Br J Cancer. 2009;101(11):1833–1838. - PMC - PubMed

    2. • Provides critical insights into the limitations of PSA screening, particularly in the gray zone, highlighting the necessity of more accurate predictive tools.

    1. Zheng Y, Li W, Zhang Y, et al. Prebiopsy bpMRI and hematological parameter-based risk scoring model for predicting outcomes in biopsy-naive men with PSA 4–20 ng/mL. Sci Rep. 2022;12(1):21895. - PMC - PubMed